Newsroom

This section keeps you updated on any major development throughout the course of the TIMESPAN project.

Project News

• 20 December 2024

  WP4 paper finally submitted!

  Finally submitted! 🎉 We are excited to soon share our research on how genetics contribute to medication discontinuation in ADHD.

  Stimulant medications are the first-line treatment for ADHD, but over 50% of individuals discontinue them within two years. Our study, involving 18,362 individuals from the iPSYCH cohort, aimed to uncover the genetic factors behind this.

  Key findings:

  • No genome-wide significant loci were identified.
  • Potential genetic differences in discontinuation between children and adults.
  • Higher polygenic risk scores (PRS) for psychiatric disorders linked to increased discontinuation.
  • Adults showed a higher SNP-heritability for discontinuation compared to children.
  • Rare deleterious variants in dopamine-related genes were less common in those who discontinued medication, especially in adults.

  Our results suggest that genetics may play a slightly stronger role in medication discontinuation in adults compared to children. Stay tuned for more insights and check out the abstract here: https://www.sciencedirect.com/science/article/abs/pii/S0924977X24003390

  

  This post was provided by Isabell Brikell.

• 12 December 2024

  New Insights on Long-Term ADHD Treatment and Its Link to Cardiovascular Disease

  ADHD medications, particularly stimulants like methylphenidate and amphetamines, are widely recognized for their effectiveness in managing ADHD symptoms. However, they are also known to increase heart rate and blood pressure in the short term. With a growing number of adults being diagnosed and prescribed these medications for extended periods, questions about adherence patterns and safety, particularly potential risks of cardiovascular disease (CVD), have become increasingly relevant. As individuals with ADHD age and their risk for CVD naturally rises, robust evidence is crucial to guide safe and effective long-term treatment strategies.

  Recent research from TIMESPAN sheds new light on ADHD medication usage trends and their potential health implications:

  • High Discontinuation Rates: Over 50% of teens, young adults, and adults discontinue ADHD medication within a year. Among children, the rate is slightly lower at 35%. The transition to adult psychiatric care, particularly at ages 18–19, is a critical period when patients risk losing consistent care, leading to higher discontinuation rates.
  • Country-Specific Patterns: Significant differences in discontinuation rates are seen across countries. For example, in Denmark, only 18% of children stop treatment within a year, compared to an average of 35% in other Nordic countries. This disparity may reflect Denmark’s stricter prescribing practices compared to countries like Sweden, where ADHD medication use is more common.
  • Long-Term Cardiovascular Risks: A large-scale analysis of over 275,000 Swedish individuals revealed that long-term use of ADHD medication was associated with a 4% annual increase in cardiovascular disease risk, particularly hypertension and arterial disease. The risks were most pronounced at doses exceeding 1.5 times the defined daily dose (DDD).

  Implications

  These findings underscore the importance of a comprehensive approach to managing ADHD treatment, balancing symptom control with safety considerations:

  • Improved Transition Support: Strengthening the transition from child to adult psychiatric care could help reduce discontinuation rates during this vulnerable period.
  • Innovative Adherence Tools: Digital interventions, such as SMS reminders, could support patients in maintaining adherence to their treatment plans.
  • Heart Health Monitoring: Although the absolute risk of CVD remains low, physicians should monitor cardiovascular symptoms in patients on long-term or high-dose ADHD medication.

  This research emphasizes the importance of balancing the benefits of ADHD medication with a proactive approach to long-term health, ensuring patients can manage their symptoms effectively while minimizing potential risks. Patients should work closely with their healthcare providers to ensure their treatment is effective and safe, with regular follow-ups and adjustments as needed.

  Read the full study details in The Lancet Psychiatry and JAMA Psychiatry.

  

  

  Article was provided by Zheng Chang and Lin Li

• 4 December 2024

  The value of pre-registration in psychiatric research.

  The value of open science and reproducible research has been increasingly recognized in contemporary psychiatric research. It is also a key component of TIMESPAN. We aim for pre-registration of protocols on relevant platforms along with the final version of the R code (e.g., https://osf.io/). Our open science strategy also highlight the value of providing a description of how to access raw data for each data source (with online materials typically included in data sharing statements), and whenever possible, presenting aggregated raw data for all study variables in the appendix of publications.

  I recently co-authored an editorial, together with Dr Jessie Baldwin, to describe how open science and reproducible research practices in psychiatric research can be implemented through registered reports. Registered Reports are a format of article in which the study protocol is pre‐registered and peer‐reviewed before the research is conducted. If the protocol is of high quality and the proposed research topic is important, the journal will commit to publishing the study regardless of the results. This article format crucially addresses publication bias, as decisions on publication are entirely independent of the results. Among many things, our editorial provided recommendations to consider when preparing a Registered Report. 

  • Ensure that your study addresses an important research question, using high quality, robust methods. Describe the methods in sufficient detail to allow replication and prevent undisclosed flexibility in the analysis.
  • Make analytic code openly available on GitHub or the Open Science Framework
  • When possible, make data and materials openly available. 
  • Consider collaboration with relevant stakeholders such as patients, families, and communities with lived experience throughout the research process to ensure that studies are relevant, ethical, and impactful.

  Learn more about open science and reproducible research and also about Registered Reports by reading our editorial.

  

  This post was written by TIMESPAN coordinator Prof Dr Henrik Larsson.

• 19 November 2024

  8th TIMESPAN Steering Committee Meeting

  🌟 A day of productive collaboration for TIMESPAN!
  Today’s Steering Committee (SC) meeting brought our team together to review progress, share insights, and chart the next steps in advancing research on ADHD and co-occurring cardiometabolic diseases.

  Collaboration like this is what helps us move closer to meaningful, patient-centered outcomes. Stay tuned for exciting updates in the months ahead!

• 14 November 2024

  World Diabetes Day 2024

  🌍 It’s #WorldDiabetesDay. Did you know that TIMESPAN research explores the link between maternal diabetes and childhood ADHD risk? Unlike previous studies showing a higher risk, our study of 3.6 million mother–child pairs across seven countries found only a small-to-moderate association between maternal diabetes and ADHD in offspring.
  This underscores the importance of investigating genetic and environmental factors. 🌐

  Read more in our latest article in Nature Medicine: “Maternal diabetes and risk of ADHD in offspring”
  🔗  https://www.nature.com/articles/s41591-024-02917-8

• 10 October 2024

  World Mental Health Day 2024

  People with Attention-Deficit/Hyperactivity Disorder (ADHD) often face mental health challenges that can greatly affect their overall well-being. Here’s what research shows:
  🧠 Adults with ADHD tend to have worse mental health than those without ADHD.
  🧠 50% of adults with ADHD report severe symptoms of depression, anxiety, and stress (Ogrodnik et al., 2023).
  🧠 Only 42% of adults with ADHD achieve full mental well-being, compared to 73.8% of people without ADHD (Fuller-Thomson et al., 2022).
  
  These findings highlight the importance of timely diagnosis and personalized treatment for individuals with ADHD, as addressing their unique mental health needs is crucial for improving their overall quality of life.

  Watch our informational video here: https://youtube.com/shorts/2US4pLcQDeU

  
  

• 1 October 2024

  October is ADHD Awareness Month!

  It’s ADHD Awareness Month 2024! Our goal is to enhance the clinical management of chronic cardiometabolic conditions, such as obesity and type 2 diabetes, in adults with ADHD. 🧠
  
  More info:
  🌐 TIMESPAN: https://timespan.eu/
  🌐 ADHD Awareness Month: adhdawarenessmonth.org
  
  Make sure to also check out the program organized by ADHD-Europe centered around this year’s theme “Awareness is Key”:
  1st Oct, 12.30pm CET – Live with Q&A
  Better Lives Together with a Positive Attitude

  21st Oct, 12pm CET – Live with Q&A
  The HyperActive Dreamers – Education that’s Fits ALL

  24 Oct, 7pm CET – Panel Webinar
  ADHD Women Experts + Professional Healthcare ADHD Group Members
  
  

• 25 September 2024

  New publication: Cumulative ADHD medication use and risk of type 2 diabetes

  We are excited to announce the publication of TIMESPAN’s latest study in BMJ Mental Health, examining the relationship between cumulative ADHD medication use and the risk of type 2 diabetes (T2D) in adults. This study is one of the largest of its kind, analyzing over 138,000 individuals with ADHD in Sweden, tracked between 2007 and 2020.

  Key Findings:

  The research found that overall, ADHD medications do not increase the risk of developing type 2 diabetes, which is an important finding for individuals managing ADHD. However, there are some important nuances in the results:

  • Methylphenidate, the most common ADHD medication, was not associated with an increased risk of type 2 diabetes.
  • Lisdexamfetamine showed no significant association with type 2 diabetes.
  • However, long-term use of atomoxetine (more than 3 years) was linked to a slightly higher risk of developing type 2 diabetes (44% increased risk).

  Implications for Clinical Practice:

  These findings suggest that clinicians should be aware of the potential metabolic risks, especially with long-term use of atomoxetine. Regular monitoring and patient-specific strategies will help manage both ADHD symptoms and potential cardiometabolic risks. The study calls for further research to confirm these results and explore mechanisms behind this association.

  For more information, please refer to the full article in BMJ Mental Health: https://mentalhealth.bmj.com/content/27/1/e301195

• 28 August 2024

  TIMESPAN at #ECNP2024

  We’re excited to share that TIMESPAN members will be present at prestigious ECNP Congress 2024 in Milan, Italy.
  Held from 21st to 24th September 2024, the congress promises to be the largest meeting in applied and translational neuroscience.

  Join our TIMESPAN symposium “Treatment of ADHD across the lifespan: monitoring and predicting outcome” on Tuesday, 24th September, from 08:30 to 09:50 am in Gold Plenary.

  • Chair: Zheng Chang, Sweden (Karolinska Institutet)
  • Isabell Brikell, Sweden (Karolinska Institutet and Aarhus University): Patterns and predictors for ADHD treatment use and discontinuation across the lifespan: a multi-national investigation
  • Catharina A. Hartman, Netherlands (University of Groningen): Somatic comorbidity in individuals with ADHD, including links with medication
  • Hayley Denyer, United Kingdom (King’s College London): Using remote measurement technology to identify real-world consequences of ADHD medication treatment initiation in adults with ADHD
  • Ditte Demontis, Denmark (Aarhus University): Genetic architecture of childhood maltreatment and suicide attempt in ADHD and other psychiatric disorders
• 22 July 2024

  World Brain Day 2024

  TIMESPAN celebrates World Brain Day. #WBD2024 is dedicated to Brain Health and Prevention

  We aim to improve the clinical management of chronic cardiometabolic diseases, such as obesity or type 2 diabetes in adult patients with ADHD.

  Also, we explore patterns in their treatment behaviour – Do people with ADHD take their meds regularly? If not, why? And what could be improved?

• 24 June 2024

  TIMESPAN Podcast: Observations from Finnish ADHD Association, with Nina Hovén (ep 2)

  Welcome to the TIMESPAN Podcast! A format that gives a stage to different perspectives of people with ADHD.
  In our second episode we join Nina Hovén as she shares insights about how ADHD is managed in her home country Finland and what ADHD Associations need to do in the future!

  Nina Hovén is Executive Director at ADHD Liitto ry, the Finnish ADHD Organisation, which was founded in 1989.
  Nina joined ADHD Liitto ry in 2012 and since 2023, she was elected as president of ADHD Europe until end of term 2026.

• 17 June 2024

  Postdoctoral Position in Prof. Steve Faraone’s Lab

  We are seeking a highly motivated and talented Postdoctoral Researcher to conduct predictive modeling analyses using machine learning and deep learning.  This position could either be on-site or remote. The postdoctoral associate will work with a multidisciplinary team to develop novel algorithms for predicting mental disorder diagnosis and prognosis, assessing the effects of treatments, facilitating a better understanding of the comorbidity and clinical outcomes of ADHD and related disorder.

  Applicants must have a PhD in Neuroscience, Psychology, Computer Science/Vision, Data Sciences, or a related field.

  Experience and Preferred Skills:

  • Works independently on research projects designed by a mentor.
  • Experience in neuroscience, psychology, or psychiatric research.
  • Experience in machine learning and statistical analysis.
  • Programming skills and/or statistical skills (Python, R, or STATA/SAS/SPSS).
  • Experience with deep-learning software (Pytorch and TensorFlow).
  • Proficient level of comfort and expertise in handling large data.
  • Exceptional candidates with a demonstrated track record and experience in data science, machine learning, and/or psychiatric research.

  Applicants should send their CV and a one page description of their background and future goals to Ms Pat Forken:  forkenp@upstate.edu

• 12 June 2024

  Diabetes Awareness Week #2

  It’s #DiabetesWeek! We would like to raise awareness, backed by science and highlight scientific articles from TIMESPAN members. Read our first post here.
  A recent study in renowned journal Diabetes Research and Clinical Practice examined the effects of ADHD and ADHD treatment on glycemic management in type 1 diabetes.

  Conducting a systematic review and meta-analysis of observational studies, researchers found that mean HbA1c levels were significantly higher in T1D individuals with ADHD compared to those without ADHD. The rates of suboptimal HbA1c levels, hospitalization, diabetic ketoacidosis, and hypoglycemia were all substantially higher in T1D individuals with ADHD than those without ADHD. No difference was found in mean HbA1c between those who received ADHD treatment and those who did not.

  The authors concluded that identifying and addressing ADHD symptoms in T1D can improve glycemic management, and help prevent acute diabetes-related complications.

  Read the full publication here: https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(24)00049-4/

• 10 June 2024

  Diabetes Awareness Week #1

  It’s #DiabetesWeek! A recent study in nature medicine examined the link between maternal diabetes mellitus and ADHD.
  Analyzing 3.6 million mother-child pairs, researchers found a small-to-moderate risk of ADHD in children exposed to maternal diabetes mellitus. The association between gestational diabetes mellitus and ADHD is unlikely to be causal.
  This finding contrast with previous studies, which reported substantially higher risk estimates, and underscores the need to reevaluate the precise roles of hyperglycemia and genetic factors in the relationship between MDM and ADHD.

  The study is open access via: https://doi.org/10.1038/s41591-024-02917-8

• 14 May 2024

  Paper awarded Publication of the Year!

  🏆 CONGRATS! Isabell Brikell has been awarded the “Publication of the Year” prize by the Department of Global Public Health and Primary Care (IGS), University of Bergen (UiB). We’d like to extend this congratulations to Lin Li and Honghui Yao, who contributed equally to the paper.
  The winning publication is titled “ADHD medication discontinuation and persistence across the lifespan: a retrospective observational study using population-based databases.”
  Read the paper here.
  
  Special congrats also to Kari Klungsøyr and Zheng Chang, as well as to all authors. As always, science is a group effort!

  

  

• 16 April 2024

  TIMESPAN’s 4th General Assembly Meeting

  🌟 Reflecting on an important event for TIMESPAN! 🧠
  Last week, we convened for our fourth General Assembly Meeting in Copenhagen, Denmark, where we engaged in in-depth discussions covering our different work packages.
  A highlight ✨ was our posterwalk, where TIMESPAN’s Early Career Researchers presented their work and received valuable feedback.
  
  It was an inspiring meeting filled with insightful discussions and strategic planning for the future of our project.
  
  The dedication and collaboration of our international team continues to drive our project forward.
  
  A huge thank you to everyone who participated and contributed to making this meeting a success! Onward and upward! 💪

  

• 8 April 2024

  Article in nature medicine: Maternal diabetes and risk ofattention-deficit/hyperactivity disorderin offspring in a multinational cohortof 3.6 million mother–child pairs

  Many TIMESPAN members have contributed to this multinational cohort study with linked mother–child pairs data in Hong Kong, New Zealand, Taiwan, Finland, Iceland, Norway and Sweden to evaluate associations between maternal diabetes mellitus (MDM) and ADHD. The team studied over 3.6 million mother-child pairs and showed that children who were born to mothers with any type of diabetes during pregnancy had a higher risk of ADHD than unexposed children (pooled hazard ratio (HR) = 1.16, 95% confidence interval (CI) = 1.08-1.24).

  However, siblings with discordant exposure to GDM in pregnancy had similar risks of ADHD (pooled HR = 1.05, 95% CI = 0.94-1.17), suggesting potential confounding by unmeasured, shared familial factors.
  The findings indicate that there is a small-to-moderate association between MDM and ADHD.

  Read the full paper here: https://doi.org/10.1038/s41591-024-02917-8

• 4 April 2024

  Upcoming: TIMESPAN’s 4th GA Meeting

  Packed your suitcases and prepared all slides, yet? It’s less than a week until the TIMESPAN consortium meets again in-person, and for our colleagues who can’t make it to beautiful Copenhagen, there will be a hybrid option. During our 4th General Assembly Meeting, we’ll be discussing the project’s progress, its achievements so far, and plan ahead for the year to come.

• 3 April 2024

  ART-CARMA enrolled the 200th patient

  The ART-CARMA team have now enrolled 200 participants into the study! A huge thank you to the data collection teams in both London and Barcelona and to all of our participants!

  Follow KCL’s ADHD RemoteTech team and TIMESPAN on X (formerly Twitter)!

• 2 April 2024

  New paper: Associations between ADHD genetic liability and ICD-10 medical conditions in adults.

  In a Phenome-Wide Association Study (PheWAS), using data from the Estonian Biobank and genetic risk scores related to ADHD, this study found strong links with chronic obstructive pulmonary disease (COPD), obesity, and Type-2 diabetes.

  The article, titled “Associations between attention-deficit hyperactivity disorder genetic liability and ICD-10 medical conditions in adults: utilizing electronic health records in a Phenome-Wide Association Study” is authored by Ellis Haan, Kristi Krebs, Urmo Võsa, Isabell Brikell, Henrik Larsson, Kelli Lehto and the Estonian Biobank Research Team.

• 12 March 2024

  New paper: ADHD-medication linked to reduced mortality

  A recent study published in JAMA by Lin Li et al. titled “ADHD Pharmacotherapy and Mortality in Individuals With ADHD” researchers also from TIMESPAN reveals a correlation between ADHD medication usage and a decreased likelihood of premature death. The findings suggest that the risk of death from unnatural causes, such as accidents and overdoses, may be reduced by 25% with ADHD medication.

  The study showed that there is a link between initiation of medication and a lower risk of death. “This was true regardless of the cause of death, but the risk of dying from unnatural causes, such as alcohol and drug overdose, decreased the most. The association was not as strong for the risk of dying from natural causes as physical health conditions,” says Lin Li, postdoctoral researcher at the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet and first author of the study.

• 22 February 2024

  New paper in Nature Reviews Disease Primers: Attention-deficit/hyperactivity disorder

  In this comprehensive Nature review by Stephen V. Faraone, Mark A. Bellgrove, Isabell Brikell, et al., three authors—Stephen Faraone, Isabell Brikell and Catharina A. Hartman—were supported by TIMESPAN. Congrats team!

  Key facts:

  • Attention-deficit/hyperactivity disorder is a common neurodevelopmental condition that affects children and adults worldwide.
  • ADHD has a predominantly genetic aetiology that involves common and rare genetic variants.
  • Some environmental correlates of the disorder have been discovered but causation has been difficult to establish.
  • The heterogeneity of the condition is evident in the diverse presentation of symptoms and levels of impairment, the numerous co-occurring mental and physical conditions, the various domains of neurocognitive impairment, and extensive minor structural and functional brain differences.
  • The diagnosis of ADHD is reliable and valid when evaluated with standard diagnostic criteria.
  • Curative treatments for ADHD do not exist but evidence-based treatments substantially reduce symptoms and/or functional impairment.
  • Medications are effective for core symptoms and are usually well tolerated.
  • Some non-pharmacological treatments are valuable, especially for improving adaptive functioning.
  • Clinical and neurobiological research is ongoing and could lead to the creation of personalized diagnostic and therapeutic approaches for this disorder.

  Read the full publication here.

• 30 January 2024

  Keynote lecture #2: The Impact of Microbiota on Host Diseases and Drugs Using Estonian Microbiome Cohort Data by Prof. Elin Org

  What is the microbiome? How does it affect human health and mental health?

  New keynote now live!

  Learn about the Gut-Brain Connection and the association between microbiome and diseases.

  We invited Dr. Elin Org, associate professor at the University of Tartu as keynote speaker to talk about The Impact of Microbiota on Host Diseases and Drugs Using Estonian Microbiome Cohort Data.

• 10 December 2023

  How can we improve the management of individuals with attention deficit hyperactivity disorders and co-occurring cardiometabolic disease?

  Read in, as Prof. Dr. Henrik Larsson, coordinator of the TIMESPAN project, discusses the questions

  • Why improve the management of cardiometabolic disease in ADHD?
  • Which knowledgegaps need to be addressed?

  Click here to read the full review article.

• 30 November 2023

  Masterclass #3: ADHD Biomarkers by Prof. Dr. Jan Buitelaar

  Prof. Dr. Jan Buitelaar, professor of child and adolescent psychiatry at Radboud University Medical Center, provides a thorough overview of current research on ADHD biomarkers in this masterclass. He delves into several reviews and meta-analytical papers on different types of biomarkers, and highlights the principles and validation processes of biomarkers in general. The session is enriched with insightful examples from biomarker research, offering a deep and engaging exploration of this intricate field.

  Watch the masterclass in our masterclass section or directly on YouTube.

• 27 November 2023

  New paper on psychiatric comorbidities in women with and without ADHD in Iceland

  A cross-sectional analysis of the nationwide, all-female, population-based SAGA Cohort Study has been published in BMC Medicine. Congratulations to the team!

  Conclusion: ADHD is overrepresented among women with cardiometabolic conditions and contributes to other psychiatric comorbidities.

  Click here to read full article.

• 27 November 2023

  First multinational study from TIMESPAN published

  “Early medication discontinuation is common in ADHD across countries, which can represent a major barrier to positive treatment outcomes.”

  The first multinational study published in Lancet Psychiatry reveals key insights into ADHD medication discontinuation covering 9 countries and regions. Our research shows early discontinuation is common, particularly in young adults. Read full article here.

  Congratulations to the team!

• 22 November 2023

  New paper from our TIMESPAN colleagues using Swedish register data

  Is long-term use of attention-deficit/hyperactivity disorder (ADHD) medication associated with an increased risk of cardiovascular disease (CVD)?

  This nationwide study found long-term exposure to ADHD medication was associated with increased risk of cardiovascular disease; therefore, the potential risks and benefits of long-term ADHD medication use should be carefully weighed.

  Click here to read full article.

• 10 November 2023

  ART-CARMA study reaches two big milestones

  In November, we reached two big milestones in WP5 – the first ART-CARMA study participant has finished their 12-month remote-monitoring period and we are halfway through the recruitment now (150 participants enrolled). Thank you to all of our participants for your valuable input and to the data collection teams in London and Barcelona!

• 2 November 2023

  TIMESPAN at ODISSEI conference 2023

  Last week, Catharina Hartman of Partner UMCG presented during the ODISSEI conference: “The association between Attention Deficit Hyperactivity Disorder and treatment discontinuation for Type 2 Diabetes Mellitus: research based on a nationwide population-based cohort study in the Netherlands”

  Yiran Li, also of UMCG, presented her poster with the title “Cardiometabolic diseases of people with Autism Spectrum Disorder: a nationwide population-based cohort study in the Netherlands”.

  

  

• 24 October 2023

  TIMESPAN Podcast: Perspectives of people with ADHD. Andrea Bilbow, OBE (ep 1)

  Welcome to the TIMESPAN Podcast! A format that gives a stage to different perspectives of people with ADHD. In the very first episode, Andrea Bilbow (OBE), shares her personal ADHD journey. Andrea Bilbow is founder and CEO at ADDISS the UK National Attention Deficit Disorder Information and Support Service, which she founded in 1995.

  Citing her own words, Andrea is the poster girl for TIMESPAN, as our main objective is to advance the management of adult attention deficit hyperactivity disorder and co-occurring cardiometabolic disease. Emerging evidence points at substantial comorbidity and shared genetics between adult ADHD and cardiometabolic diseases i.e., Obesity, Type 2 Diabetes and cardiovascular disease (CVD). However, screening, diagnosis and treatment guidelines for ADHD patients with these diseases do not exist. TIMESPAN builds on real-world data from daily clinical practice, but will also collect new detailed data through Remote Measurement Technology (RMT) to allow for improved identification of ADHD patients at risk for cardiometabolic outcomes and improved multidisciplinary and personalized treatment approaches. TIMESPAN is an EU-funded research project led by international recognised leaders working together on an interdisciplinary basis, consisting of clinicians, epidemiologists, biostatisticians, geneticists and artificial intelligence computer scientists.

• 27 September 2023

  TIMESPAN members receive Kramer-Pollnow Prize!

  Last week, our TIMESPAN members Kenneth Man (from UCL in London) and Zheng Chang (from Karolinska Institutet in Stockholm) were awarded the Kramer-Pollnow Prize for scientific excellence in the research on ADHD!

  Congratulations!

  The prize was presented at this year’s EUNETHYDIS members meeting in Montpellier, France.

  The Kramer-Pollnow Prize is awarded every two years for scientific excellence in research in child and adolescent psychiatry.

  

• 6 September 2023

  Keynote lecture #1: Epidemiological conditions of cardiovascular diseases by Pontus Andell, MD, PhD

  Pontus Andell, MD, PhD, associate professor at Karolinska Institutet and resident cardiologist at Karolinska University Hospital in Stockholm, Sweden, held the very first keynote lecture titled “Epidemiological conditions of cardiovascular diseases” during the General Assembly Meeting of TIMESPAN in Stockholm in May 2022.

  Learn more about which cardiovascular diseases are most relevant in ADHD, the burden of cardiovascular diseases in general, and how we can use registry-based data to study CVDs in the keynote lecture.

• 2 August 2023

  Masterclass #2: What can family data tell us about unmeasured confounding? by Ralf Kuja-Halkola, PhD

  Ralf Kuja-Halkola, PhD, researcher and statistician at Karolinska Institutet in Stockholm, Sweden, gave a masterclass titled “What can family data tell us about unmeasured confounding?” during the General Assembly Meeting of TIMESPAN in Stockholm in May 2022.

  Learn more about directed acyclic graphs and how to use them to make assumptions about associations in his masterclass.

• 22 July 2023

  World Brain Day 2023

  Every year, 22nd July marks World Brain Day, an awareness day launched by World Federation of Neurology. Even though the 2023 theme is “Brain Health and Disability: Leave No One Behind”, it is also important to talk about ADHD brains!

  ADHD is a neurodevelopmental condition with traits and behaviours stemming from a different brain development in key stages of brain development.

  Research has identified several potential disparities in the brains of individuals with ADHD compared to those without the condition. However, the precise significance of these variances remains uncertain.

  https://www.additudemag.com/category/adhd-add/adhd-brain/ is a great resource for understanding the neuroscience behind ADHD.

  TIMESPAN aims to improve not only the assessment of the risks involved for patients, but also to review and improve already existing treatments for patients with ADHD who also have cardiometabolic disease.

• 12 May 2023

  Meet TIMESPAN members at 9th World Congress on ADHD

  We’re excited to share that members of our consortium will present at the 9th World Congress on ADHD from 18 – 21 May, 2023 in Amsterdam, NL.

  18.05.2023:

  3:00 – 4:30 pm CET, room G107

  Dr. Zheng Chang from Karolinska, Sweden, and Prof. Ditte Demontis from Aarhus Uni, Denmark will chair the Hot topic “Advancing the understanding of ADHD treatment discontinuity using real-world data”

  Sessions include:

  • ADHD treatment discontinuation across the lifespan: A multi-national study (by Zheng Chang)
  • Adherence of ADHD medication and pharmacological treatment for cardiovascular disease (by Zheng Chang)
  • Remote measurement technology data on real-world treatment response to ADHD medication in adults with ADHD following initiation of medication (by Hayley Denyer, Kings College London)
  • Genetic loci and polygenic architecture of simulant ADHD medication discontinuation (by Prof. Ditte Demontis)

  3:00 – 4:30 pm CET, room G109

  Dr Le Zhang, will present “ADHD medications and long-term risk of cardiovascular diseases: A nationwide nested case-control study in Sweden” at Young Scientists´ Session I.

  19.05.2023:

  2:00 – 3:30 pm CET, Onyx Lounge

  The poster session “Comorbidity: adults” is chaired by TIMESPAN partner Prof. Josep Antoni Ramos Quiroga (from Fundacio Hospital Universitari Vall D’Hebron).

  In this session, Unnur Jakobsdottir Smari, of TIMESPAN partner University of Iceland, will be presenting her poster: “Anxiety and mood disorders in women with cardiometabolic conditions with and without ADHD: A population-based cross sectional study”.

  Additionally, Nina Nielsen, of our partner Aarhus University, will present her poster, titled “Association between ADHD and initiation of a lipid-lowering drug in adults: A nationwide study”.

  20.05.2023:

  3:30 – 5:00 pm CET, room G102-G103

  Prof. Jonna Kuntsi of Kings College London will be chairing the Hot Topic Session: ‘What is new in digital psychiatry in ADHD?’ and providing a talk in this session ‘ADHD Remote Technology (ART) research programme: from current research towards future clinical application’

• 17 April 2023

  Successful meeting: TIMESPAN’s third General Assembly

  TIMESPAN’s 3^rd General Assembly Meeting took place in Tallinn, Estonia from 12 – 14 April, 2023. The meeting started with a masterclass given by Prof. Jan Buitelaar from Radboud University Medical Center and a keynote lecture by Dr. Elin Org from the University of Tartu.

  During the two main meeting days, work package leaders and members have presented and discussed their scientific data and the overall progress of their work. Thanks to invaluable discussions, the consortium is now full of beans for the months to come.

• 28 November 2022

  TIMESPAN´s first ECS Journal Club

  The 1st TIMESPAN ECS Journal Club, started with Hayley Denyer´s brilliant presentation about the ADHD Remote Technology (‘ART’) pilot study. Thanks to all involved for livening up the discussion and for sharing knowledge!

• 9 November 2022

  Intensive and successful 4th SC-Meeting

  What an intensive 4th SC-Meeting! We were delighted meeting all TIMESPAN partners again and hear about #TIMESPAN ´s big #progress on #management of #chronic#cardiometabolic disease and #treatment discontinuity in #adult#ADHD patients. Let´s keep up the amazing work!

  

• 24 October 2022

  TIMESPAN @ EASO: Webinar on ADHD and Obesity

  Don´t miss the EASOCOMs Webinar: ADHD and Obesity on 25th October 2022!

  When? 12.30-14.00 CEST

  TIMESPAN Prof Henrik Larsson and Prof Dr J. Antoni Ramos presenting ADHD101
  • Professor Henrik Larsson will present the register-based studies from Sweden exploring causes and consequences of obesity in ADHD
  • Professor Dr J. Antoni Ramos-Quiroga will present ADHD across lifespan

• 19 August 2022

  TIMESPAN´s Rubik´s Cube out now

  … as a digital intro version for all TIMESPAN video products..🎥

  More Details...
• 7 May 2022

  TIMESPAN webinar at ADHD Europe

  TIMESPAN coordinator Prof. Henrik Larsson from the Örebro University in Sweden gives a short webinar about the TIMESPAN project at ADHD Europe.

  👉Watch the whole webinar here.

• 1 April 2022

  Happy Birthday #1year

  Today we celebrate #oneyear of successful and amazing #work within the TIMESPAN project. Thanks to all TIMESPAN partners for all your efforts you made so far! Let’s keep on going!

  #ADHD#adhdtwitter#ADHDlife#wearables#1year#eu#H2020

• 24 February 2022

  TIMESPAN Patient Brochure

  In collaboration with ADHD Europe our new brochure for patients is available as web and print version with the most important facts of TIMESPAN and how the ART-CARMA research contributes to a healthier future for ADHD patients.

• 30 November 2021

  2nd SC Meeting

  Our 2nd SC meeting was held (once again) remote on 29 – 30 November 2021. Thank you all for your interesting updates as well as the great brainstorming sessions during the 2nd SC meeting! @orebrouni@karolinskainst@AarhusUni@UiB@researchumcg@vallhebron@KingsIoPPN@concentris_EU@EASOobesity@UpstateNews@empatica@hkumed#H2020#ADHD

• 3 October 2021

  TIMESPAN at the 34th ECNP Congress

  📢 TIMESPAN was represented today at ECNP by @IsabellBrikell. She talked about somatic health in ADHD, including results for several of the cardiometabolicdisorder we are looking into in TIMESPAN.

  ⏲️ 13:15-14:35 WEST
  🏛️ Auditorium I of the #Lisbon #Congress #Venue

• 24 September 2021

  TIMESPAN Project Brochure

  You can now access a web and a print version of the project’s info brochure with the most important facts of TIMESPAN and how the ART-CARMA research contributes to a healthier future for ADHD patients.

• 18 May 2021

  KICK-OFF TIMESPAN meeting

  The EU-funded research project TIMESPAN kicked off on May 18th – 19th 2021. The meeting was held remotely and although being held virtually it was full of vivid discussions as well as social interaction. 17 partners from all over the world joined forced evaluate the next steps that has to be taken in TIMESPAN. One of the main tasks was data harmonization as well as data access, definition of treatment discontinuity, and joined dissemination. All TIMESPAN scientific as well as ad hoc advisors also joined the meeting and provided a very valuable feedback on the project start.

• 1 April 2021

  KICK-OFF TIMESPAN project

  No April Fool’s joke, but the start of an exciting journey! Today, April 1st 2021, the 5 year-long EU-funded TIMESPAN project kicks off! 17 partners from academia, industry, and patient advocacy join forces in fostering improvements in clinical management of adults with #ADHD and co-occurring cardiometabolic disease.

  Various national guidelines on cardiometabolic disease already highlight the importance of concurrent psychiatric disorders, but there is a lack of knowledge around ADHD. TIMESPAN strives to improve clinical outcomes, as well as Quality Of Life in adult ADHD patients with cardiometabolic disease.

Events

• 11 April 2025

  Save the Date: Join Us for an Inspiring Patient and Layperson Event!

  We’re excited to announce TIMESPAN’s upcoming event:
  “New Vantage Points in ADHD, Obesity, and Cardiometabolic Health: Where Research Meets Patients.”

  📅 Date: 11th April 2025
  📍 Location: London, UK

  Don’t miss this opportunity to connect, learn, and engage with experts and individuals from the ADHD and cardiometabolic health communities. Save the date and stay tuned for more details!

  

• 28 August 2024

  TIMESPAN at #ECNP2024

  We’re excited to share that TIMESPAN members will be present at prestigious ECNP Congress 2024 in Milan, Italy.
  Held from 21st to 24th September 2024, the congress promises to be the largest meeting in applied and translational neuroscience.

  Join our TIMESPAN symposium “Treatment of ADHD across the lifespan: monitoring and predicting outcome” on Tuesday, 24th September, from 08:30 to 09:50 am in Gold Plenary.

  • Chair: Zheng Chang, Sweden (Karolinska Institutet)
  • Isabell Brikell, Sweden (Karolinska Institutet and Aarhus University): Patterns and predictors for ADHD treatment use and discontinuation across the lifespan: a multi-national investigation
  • Catharina A. Hartman, Netherlands (University of Groningen): Somatic comorbidity in individuals with ADHD, including links with medication
  • Hayley Denyer, United Kingdom (King’s College London): Using remote measurement technology to identify real-world consequences of ADHD medication treatment initiation in adults with ADHD
  • Ditte Demontis, Denmark (Aarhus University): Genetic architecture of childhood maltreatment and suicide attempt in ADHD and other psychiatric disorders
• 16 April 2024

  TIMESPAN’s 4th General Assembly Meeting

  🌟 Reflecting on an important event for TIMESPAN! 🧠
  Last week, we convened for our fourth General Assembly Meeting in Copenhagen, Denmark, where we engaged in in-depth discussions covering our different work packages.
  A highlight ✨ was our posterwalk, where TIMESPAN’s Early Career Researchers presented their work and received valuable feedback.
  
  It was an inspiring meeting filled with insightful discussions and strategic planning for the future of our project.
  
  The dedication and collaboration of our international team continues to drive our project forward.
  
  A huge thank you to everyone who participated and contributed to making this meeting a success! Onward and upward! 💪

  

• 10 April 2024

  TIMESPAN’s 4th GA meeting

  We look forward to meeting the consortium members April 10 – 12, 2024.

• 4 April 2024

  Upcoming: TIMESPAN’s 4th GA Meeting

  Packed your suitcases and prepared all slides, yet? It’s less than a week until the TIMESPAN consortium meets again in-person, and for our colleagues who can’t make it to beautiful Copenhagen, there will be a hybrid option. During our 4th General Assembly Meeting, we’ll be discussing the project’s progress, its achievements so far, and plan ahead for the year to come.

• 9 November 2023

  TIMESPAN 6th SC meeting

  Our 6th Steering Committee meeting will be held remotely on November 9th, 2023. During this full-day meeting, we look forward to hearing about the work packages’ progress, productive discussions and expertise sharing.

• 7 October 2023

  TIMESPAN at ECNP2023

  The European College of Neuropsychopharmacology (ECNP), an independent scientific association dedicated to the science and treatment of disorders of the brain, again hosts its annual congress. We’re delighted that members of TIMESPAN will be attending the 36th edition of the ECNP congress.
  📅 7 – 10 October 2023
  📍 Barcelona, Spain

  More info on the congress here.

• 12 May 2023

  Meet TIMESPAN members at 9th World Congress on ADHD

  We’re excited to share that members of our consortium will present at the 9th World Congress on ADHD from 18 – 21 May, 2023 in Amsterdam, NL.

  18.05.2023:

  3:00 – 4:30 pm CET, room G107

  Dr. Zheng Chang from Karolinska, Sweden, and Prof. Ditte Demontis from Aarhus Uni, Denmark will chair the Hot topic “Advancing the understanding of ADHD treatment discontinuity using real-world data”

  Sessions include:

  • ADHD treatment discontinuation across the lifespan: A multi-national study (by Zheng Chang)
  • Adherence of ADHD medication and pharmacological treatment for cardiovascular disease (by Zheng Chang)
  • Remote measurement technology data on real-world treatment response to ADHD medication in adults with ADHD following initiation of medication (by Hayley Denyer, Kings College London)
  • Genetic loci and polygenic architecture of simulant ADHD medication discontinuation (by Prof. Ditte Demontis)

  3:00 – 4:30 pm CET, room G109

  Dr Le Zhang, will present “ADHD medications and long-term risk of cardiovascular diseases: A nationwide nested case-control study in Sweden” at Young Scientists´ Session I.

  19.05.2023:

  2:00 – 3:30 pm CET, Onyx Lounge

  The poster session “Comorbidity: adults” is chaired by TIMESPAN partner Prof. Josep Antoni Ramos Quiroga (from Fundacio Hospital Universitari Vall D’Hebron).

  In this session, Unnur Jakobsdottir Smari, of TIMESPAN partner University of Iceland, will be presenting her poster: “Anxiety and mood disorders in women with cardiometabolic conditions with and without ADHD: A population-based cross sectional study”.

  Additionally, Nina Nielsen, of our partner Aarhus University, will present her poster, titled “Association between ADHD and initiation of a lipid-lowering drug in adults: A nationwide study”.

  20.05.2023:

  3:30 – 5:00 pm CET, room G102-G103

  Prof. Jonna Kuntsi of Kings College London will be chairing the Hot Topic Session: ‘What is new in digital psychiatry in ADHD?’ and providing a talk in this session ‘ADHD Remote Technology (ART) research programme: from current research towards future clinical application’

• 17 April 2023

  Successful meeting: TIMESPAN’s third General Assembly

  TIMESPAN’s 3^rd General Assembly Meeting took place in Tallinn, Estonia from 12 – 14 April, 2023. The meeting started with a masterclass given by Prof. Jan Buitelaar from Radboud University Medical Center and a keynote lecture by Dr. Elin Org from the University of Tartu.

  During the two main meeting days, work package leaders and members have presented and discussed their scientific data and the overall progress of their work. Thanks to invaluable discussions, the consortium is now full of beans for the months to come.

• 28 November 2022

  TIMESPAN´s first ECS Journal Club

  The 1st TIMESPAN ECS Journal Club, started with Hayley Denyer´s brilliant presentation about the ADHD Remote Technology (‘ART’) pilot study. Thanks to all involved for livening up the discussion and for sharing knowledge!

• 24 October 2022

  TIMESPAN @ EASO: Webinar on ADHD and Obesity

  Don´t miss the EASOCOMs Webinar: ADHD and Obesity on 25th October 2022!

  When? 12.30-14.00 CEST

  TIMESPAN Prof Henrik Larsson and Prof Dr J. Antoni Ramos presenting ADHD101
  • Professor Henrik Larsson will present the register-based studies from Sweden exploring causes and consequences of obesity in ADHD
  • Professor Dr J. Antoni Ramos-Quiroga will present ADHD across lifespan

• 23 June 2021

  ART-CARMA study

  Focus group is currently established. The KCL team around Jonna Kuntsi is currently establishing a focus group who should be involved in the discussions on how to incorporate remote technology in the ADHD assessment and initial period of starting medication. In case you are interested in the participation please get in contact with: Hayley Denyer